Overview of chemotherapy for pancreatic cancer.

摘要: Of more than 30 anticancer drugs evaluated in advanced pancreatic cancer, only 5-FU has a response rate with 95% confidence intervals greater 20%. Although mitomycin-C, streptozotocin, and doxorubicin are frequently used combination regimens, their single-agent activity cancer is marginal. The improved rates initially reported some Phase II trials of drug combinations have not been confirmed most cooperative group trials. When partial responses obtained, they brief rarely associated clinical benefit. Median survival for regimens range from 3 to 6.5 mo probably no longer those obtained 5-FU. Radiotherapy combined prolongs patients who undergo curative resection tumor confined the pancreas locally disease. Radiation imaging techniques that sophisticated available at time initial randomized now available. More effective treatments needed all disease stages may evolve as understanding etiology, growth regulation, resistance increases. Since results currently treatment poor, should be offered opportunity participate